Ariad Prepares For Early Launch Of CML Drug Ponatinib
Executive Summary
After filing a rolling submission for accelerated approval for wholly-owned Bcr-Abl inhibitor ponatinib in late July, Ariad plans to build a full commercial operation in the U.S. by the end of October.
You may also be interested in...
Financings Of The Fortnight Expects An Increase In Life Sciences IPOs In 2013
Plus news of recent financings by the Pfizer animal health spin-out Zoetis, Bone Therapeutics, Ariad Pharmaceuticals and Foresight Capital Management.
Teva’s Synribo: Salvage Therapy, But Not Personalized Medicine
Omacetaxine finds new life as a salvage treatment in chronic myeloid leukemia after failing to pass FDA muster for targeted therapy in patients with a particular genetic mutation. FDA allowed Teva to pool data from two open-label studies to secure approval in a third-line setting.
Teva’s Synribo Clears FDA For Third-Line Chronic Myeloid Leukemia
Omacetaxine, which was originally submitted by ChemGenex as Omapro, demonstrated response rates of 14% to 18% in patients who had failed two or more tyrosine kinase inhibitors. It enters a crowded space that is likely to add a new member, Ariad’s ponatinib, in the coming months.